Atrogi begins human trial for muscle-preserving weight loss
Swedish biotech Atrogi has initiated human trials for its lead oral drug candidate, ATR-258, aiming to revolutionize obesity treatment by preserving muscle mass while promoting fat loss. This milestone addresses a critical challenge in metabolic medicine: ensuring that weight loss does not come at the expense of muscle, particularly for older adults whose strength and resilience are vital for healthy aging.
The ATR-258 study, led by Associate Professor Morten Hostrup from the University of Copenhagen, will evaluate the drug’s effects on muscle in overweight male volunteers over eight weeks. By mimicking exercise’s metabolic benefits, ATR-258 seeks to enhance muscle function and metabolic health, positioning itself within a broader narrative of longevity that emphasizes quality of weight loss rather than quantity.
As the obesity treatment landscape evolves, Atrogi’s approach highlights the importance of muscle health in aging. This trial could pave the way for therapies that not only manage weight but also enhance overall functional capacity, making it a critical development for longevity professionals. For further insights, I recommend exploring the full article.